

From: [Executive Assistant](#)
To: [Exemptions](#); [Mitchell, Sophie](#); [Jones, Gavin](#)
Cc: [REDACTED]
Subject: Medicines Australia – ACCC Interim Authorisation- AA1000579-Monthly report-30 October 2021 to 29 November 2021
Date: Tuesday, 30 November 2021 8:18:15 AM
Attachments: [image001.png](#)
[image002.png](#)
[image003.png](#)
[image004.png](#)

Dear ACCC Exemptions Team,

In relation to the ACCC Interim Authorisation AA1000579 (29 September 2021) and, specifically, in accordance with the Conditions of that Authorisation at paragraph 23, Medicines Australia provides the following monthly report on activities related to the Proposed Conduct.

In the period of 30 October 2021 to 29 November 2021, no meeting, discussion, development or decision between MA/GBMA Working Group members in relation to the Proposed Conduct took place, other than the meeting that occurred on 29 September 2021, which was the subject of the report by Medicines Australia, lodged with the ACCC on 5 October 2021 under the then current authorisation (AA1000486).

Medicines Australia's next monthly update will cover the period of 30 November 2021 to 29 December 2021. Additional updates will be provided to the ACCC as required and in accordance with Medicines Australia's obligations under the authorisation. Please let us know to whom Medicines Australia should direct its future reports.

We also consent to this email being published on the public register, with the appropriate privacy redactions.

This response was drafted by Medicines Australia in consultation with [REDACTED], CEO of Generic and Biosimilar Medicines Association.

Yours sincerely

[REDACTED]

[REDACTED]
Senior Executive Assistant
Medicines Australia

17 Denison Street
Deakin ACT 2600
Australia

Telephone: [REDACTED]
Email: Executive.Assistant@medicinesaustralia.com.au
Web: <https://medicinesaustralia.com.au>